Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.

Original reporting
Published Nov 5, 2026, 7:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

Guidance raise signals improved earnings outlook, but margin pressure from higher costs remains a risk.

02

Market read

Earnings guidance update is the primary catalyst for ZBH's near‑term price action.

03

What to watch

Potential supply‑chain disruptions in China and ongoing sales‑force transition may delay the upside.

Relevance 7/10Novelty 7/10Timing: post‑earnings release today

Background

Zimmer Biomet reported Q3 2026 results, noting a decline in knee sales but growth in hips and technology, and raised its 2026 guidance.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

ZBH disclosed Q3 2026 earnings with raised guidance for hip growth and outlined 2027 outlook.

Expected impact

likely upward pressure as investors price in higher hip growth and improved 2027 outlook

Evidence & confidence

Management highlighted double‑digit growth in hips and technology segments while acknowledging knee weakness, indicating a net positive earnings outlook.

Market effects

Positive guidance may lift the broader orthopedics and med‑tech sector.

U.S. med‑tech stocks could see modest gains.

Limited to investors tracking U.S. healthcare equipment makers.

Counterpoint

Knee segment weakness and higher manufacturing costs could offset hip growth, keeping the stock flat.

Key entities

  • Ivan Tornos

    CEO of Zimmer Biomet providing guidance commentary.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMedAI 8/10

Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript

Zimmer Biomet (ZBH) reported Q3 2026 net sales of $2.63B, up 3.7% in constant currency. Growth was driven by hips, S.E.T., and technology, while knees declined 2.6%. The company raised its 2026 guidance, expecting 3% to 3.5% constant currency sales growth and $8.50 to $8.60 adjusted EPS. Strategic priorities include sales force transition, robotics expansion, and diversification.